QR код

Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban

<b>Background/Objectives</b>: The aim of the present study was to develop lactose-free formulations of rivaroxaban, a novel oral anticoagulant used for the treatment and prevention of blood clotting. As a BCS Class II drug, rivaroxaban is characterized by poor solubility in aqueous media, posing a s...

Повний опис

Збережено в:
Автори: Daniel Zakowiecki, Peter Edinger, Markos Papaioannou, Michael Wagner, Tobias Hess, Jadwiga Paszkowska, Marcela Staniszewska, Daria Myslitska, Michal Smolenski, Justyna Dobosz, Grzegorz Garbacz, Dorota Haznar Garbacz
Формат: Artigo
Мова:Inglês
Опубліковано: MDPI AG 2024-11-01
Серія:Pharmaceutics
Предмети:
rivaroxaban
lactose-free formulation
excipient
calcium phosphates
pellets
MUPS
Онлайн доступ:https://www.mdpi.com/1999-4923/16/11/1485
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси